Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BJDX NASDAQ:MOTS NASDAQ:NVIV NASDAQ:SINT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBJDXBluejay Diagnostics$3.28+75.4%$1.52$1.26▼$12.45$2.79M0.542.31 million shs106.24 million shsMOTSMotus GI$0.00$0.00▼$0.04$1K1.15,076 shs16 shsNVIVInVivo Therapeutics$0.58$0.22▼$2.40$997K0.658.25 million shs1.89 million shsSINTSintx Technologies$4.35-3.8%$3.91$1.71▼$8.60$16.21M0.83119,449 shs48,036 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBJDXBluejay Diagnostics+75.40%+103.73%+129.37%+106.29%-45.74%MOTSMotus GI0.00%0.00%0.00%-66.67%-99.72%NVIVInVivo Therapeutics0.00%0.00%0.00%0.00%0.00%SINTSintx Technologies-3.76%+5.84%+2.59%+30.63%+57.04%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBJDXBluejay Diagnostics$3.28+75.4%$1.52$1.26▼$12.45$2.79M0.542.31 million shs106.24 million shsMOTSMotus GI$0.00$0.00▼$0.04$1K1.15,076 shs16 shsNVIVInVivo Therapeutics$0.58$0.22▼$2.40$997K0.658.25 million shs1.89 million shsSINTSintx Technologies$4.35-3.8%$3.91$1.71▼$8.60$16.21M0.83119,449 shs48,036 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBJDXBluejay Diagnostics+75.40%+103.73%+129.37%+106.29%-45.74%MOTSMotus GI0.00%0.00%0.00%-66.67%-99.72%NVIVInVivo Therapeutics0.00%0.00%0.00%0.00%0.00%SINTSintx Technologies-3.76%+5.84%+2.59%+30.63%+57.04%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBJDXBluejay Diagnostics 1.00SellN/AN/AMOTSMotus GI 0.00N/AN/AN/ANVIVInVivo Therapeutics 0.00N/AN/AN/ASINTSintx Technologies 2.00Hold$25.00474.71% UpsideCurrent Analyst Ratings BreakdownLatest SINT, BJDX, MOTS, and NVIV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/8/2025SINTSintx TechnologiesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025BJDXBluejay DiagnosticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025SINTSintx TechnologiesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/22/2025SINTSintx TechnologiesAscendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$28.00 ➝ $25.00(Data available from 10/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBJDXBluejay Diagnostics$250K19.55N/AN/A$10.34 per share0.32MOTSMotus GI$319K0.00N/AN/A$1.74 per share0.00NVIVInVivo TherapeuticsN/AN/AN/AN/A$6.48 per shareN/ASINTSintx Technologies$2.89M5.40N/AN/A$2.90 per share1.50Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBJDXBluejay Diagnostics-$7.72M-$125.15N/A∞N/AN/A-362.07%-299.10%11/6/2025 (Estimated)MOTSMotus GI-$12.87M-$15.64N/AN/AN/AN/AN/AN/AN/ANVIVInVivo Therapeutics-$10.49MN/A0.00N/AN/AN/A-75.04%-65.01%N/ASINTSintx Technologies-$11.02M-$50.56N/A∞N/A-674.05%-256.59%-121.32%11/11/2025 (Estimated)Latest SINT, BJDX, MOTS, and NVIV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025SINTSintx Technologies-$0.79-$0.91-$0.12-$0.91$0.40 million$0.15 million8/7/2025Q2 2025BJDXBluejay DiagnosticsN/A-$1.41N/A-$1.41N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBJDXBluejay DiagnosticsN/AN/AN/AN/AN/AMOTSMotus GIN/AN/AN/AN/AN/ANVIVInVivo TherapeuticsN/AN/AN/AN/AN/ASINTSintx TechnologiesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBJDXBluejay DiagnosticsN/A4.564.56MOTSMotus GIN/AN/AN/ANVIVInVivo TherapeuticsN/A14.3014.30SINTSintx TechnologiesN/A2.572.41Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBJDXBluejay Diagnostics18.47%MOTSMotus GI20.06%NVIVInVivo Therapeutics13.78%SINTSintx Technologies18.38%Insider OwnershipCompanyInsider OwnershipBJDXBluejay Diagnostics0.08%MOTSMotus GI0.34%NVIVInVivo Therapeutics2.45%SINTSintx Technologies4.08%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBJDXBluejay Diagnostics91.49 million1.49 millionNot OptionableMOTSMotus GI305.77 million5.75 millionNot OptionableNVIVInVivo Therapeutics63.11 million3.03 millionNot OptionableSINTSintx Technologies403.59 million3.44 millionNot OptionableSINT, BJDX, MOTS, and NVIV HeadlinesRecent News About These CompaniesSintx Technologies (NASDAQ:SINT) Cut to "Sell" at Wall Street ZenOctober 5, 2025 | americanbankingnews.comSintx Technologies files to sell 541,450 shares of common stock for holdersSeptember 30, 2025 | msn.comSeveral Insiders Invested In Sintx Technologies Flagging Positive NewsSeptember 18, 2025 | finance.yahoo.comWhy Is Sintx Technologies Stock (SINT) Down 20% Today?September 9, 2025 | msn.comSINTX Technologies to Present at the H.C. Wainwright 27th Annual Global Investment Conference on September 9, 2025September 9, 2025 | markets.businessinsider.comSintx Technologies announces exercise of warrants for $3.8M gross proceedsSeptember 8, 2025 | msn.comSintx Technologies receives USPTO notice of allowanceSeptember 8, 2025 | msn.comSINTX Technologies Announces Successful Exercise of Warrants for $3.8 Million Gross ProceedsSeptember 8, 2025 | globenewswire.comSINTX Technologies Receives USPTO Notice of Allowance for Silicon Nitride Antipathogenic Platform PatentSeptember 8, 2025 | globenewswire.comSintx Technologies Names Trask Chief Financial OfficerSeptember 6, 2025 | marketwatch.comSintx Technologies Appoints New CFO Kevin TraskSeptember 6, 2025 | msn.comSintx Technologies publishes study of antiviral activity of Silicon NitrideSeptember 3, 2025 | msn.comSintx Technologies (NASDAQ:SINT) Director Purchases 3,000 SharesAugust 28, 2025 | insidertrades.comSintx Technologies (NASDAQ:SINT) CEO Acquires $37,500.50 in StockAugust 26, 2025 | insidertrades.com3D Printing Ceramics Market worth $0.97 billion by 2030 - Exclusive Report by MarketsandMarkets™August 25, 2025 | finance.yahoo.comSintx Technologies issues business update following strategic realignmentAugust 15, 2025 | msn.comSINTX Technologies Issues Business Update Following Strategic Realignment, Leadership Expansion, and SiNAPTIC AcquisitionAugust 15, 2025 | globenewswire.comSINTX Technologies Expands Silicon Nitride Platform into Hybrid CFR-PEKK Trauma PlatesAugust 4, 2025 | globenewswire.comSINTX Technologies Submits FDA 510(k) for Silicon Nitride Foot & Ankle Medical DevicesJuly 22, 2025 | taiwannews.com.twTSintx Technologies, Inc. (SINT) - Yahoo FinanceJune 27, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSINT, BJDX, MOTS, and NVIV Company DescriptionsBluejay Diagnostics NASDAQ:BJDX$3.28 +1.41 (+75.40%) Closing price 10/9/2025 04:00 PM EasternExtended Trading$2.74 -0.54 (-16.46%) As of 05:33 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bluejay Diagnostics, Inc., a medical diagnostic company, develops rapid test for the monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge, which includes reagents and components. The company also offers ALLEREYE diagnostic test, a point-of-care device for the diagnosis of allergic conjunctivitis. In addition, it develops IL-6 for the monitoring of disease progression in critical care; as well as hsTNT/I and NT-proBNP for the monitoring of patients acuity with chest pain. The company was incorporated in 2015 and is headquartered in Acton, Massachusetts.Motus GI NASDAQ:MOTSMotus GI Holdings, Inc. operates as a medical technology company in the United States. It develops Pure-Vu system, a medical device to facilitate the cleansing of a poorly prepared gastrointestinal tract during the colonoscopy and facilitates upper gastrointestinal endoscopy procedures. The company was formerly known as Eight-Ten Merger Corp. and changed its name to Motus GI Holdings, Inc. in November 2016. The company was founded in 2008 and is based in Fort Lauderdale, Florida.InVivo Therapeutics NASDAQ:NVIVInVivo Therapeutics Holdings Corp. operates as a research and clinical-stage biomaterials and biotechnology company in the United States. The company engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries (SCI). It is developing a Neuro-Spinal Scaffold implant comprise of biocompatible and bioresorbable polymers, which includes Poly lactic-co-glycolic acid, a polymer which is widely used in resorbable sutures and provides the biocompatible support for Neuro-Spinal Scaffold implant; and Poly-L-Lysine, a positively charged polymer used to coat surfaces to promote cellular attachment. The company was incorporated in 2003 and is headquartered in Cambridge, Massachusetts. On February 1, 2024, InVivo Therapeutics Holdings Corp. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware. It is in joint administration with InVivo Therapeutics Corporation.Sintx Technologies NASDAQ:SINT$4.35 -0.17 (-3.76%) Closing price 10/9/2025 04:00 PM EasternExtended Trading$4.26 -0.09 (-1.95%) As of 10/9/2025 04:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Sintx Technologies, Inc., an advanced ceramics company, engages in the research, development, and commercialization of medical devices manufactured with silicon nitride for biomedical, technical, and antipathogenic applications in the United States. It provides solid and porous silicon nitride; silicon nitrite powder; and silicon nitride coating products, as well as silicon nitride composite materials, polyetheretherketone, and polyetherketoneketone. The company was formerly known as Amedica Corporation. Sintx Technologies, Inc. was incorporated in 1996 and is headquartered in Salt Lake City, Utah. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Amazon’s Prime Day May Be the Catalyst for a Year-End Rally AI Meets Nuclear: Palantir’s Role in Energy Expansion Buy the Dip? Zillow’s Profit Comeback Meets Market Pressure Adobe Launches Premiere Pro on iPhone, Upside Ahead? Rocket Lab: A Space Giant Hitting New Highs—Time to Chase? After AI Hyperscaler Deal, Is Aehr Test Systems Stock on Sale? Why Archer Aviation Stock Is Soaring—And What Comes Next Lithium Americas: Why This 31% Rally Is More Than Just a Headline Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
